Seeking Alpha

Shares of Medgenics (MDGN +25%) soar after the company says its Infradure Biopump has received...

Shares of Medgenics (MDGN +25%) soar after the company says its Infradure Biopump has received an Orphan Drug Designation from the FDA to treat hepatitis D. The designation carries multiple benefits, including the availability of grant money, certain tax credits and seven years of market exclusivity, as well as the possibility of an expedited regulatory process. Seeking Alpha contributor Ray Dirks says the designation makes it a prime takeout target.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector